✦ LIBER ✦

Response to tyrosine kinase inhibitors in chronic myeloid leukemia: experience from a west Asian developing country

✍ Scribed by Ali, Mohammed Dhahir; Badi, Ameer I.; Al-Zebari, Shaima S. M.; Al-Allawi, Nasir A. S.

Book ID: 125815596
Publisher: Carden Jennings Publishing
Year: 2014
Tongue: English
Weight: 316 KB
Volume: 100
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-014-1627-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Molecular monitoring in chronic myeloid

Molecular monitoring in chronic myeloid leukemia : Response to tyrosine kinase inhibitors and prognostic implications

✍ Elias Jabbour; Jorge E. Cortes; Hagop M. Kantarjian 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB

## Abstract The majority of patients with chronic‐phase (CP) chronic myeloid leukemia (CML) who are treated with Bcr‐Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve cytogenetic disease remission (ie, Philadelphia chromosome‐positive cells undetectable by cytogenetic evaluation

BCR-ABL1 RT-qPCR for Monitoring the Mole

BCR-ABL1 RT-qPCR for Monitoring the Molecular Response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

✍ Press, Richard D.; Kamel-Reid, Suzanne; Ang, Daphne 📂 Article 📅 2013 🏛 American Society for Investigative Pathology 🌐 English ⚖ 720 KB

Philadelphia-negative acute promyelocyti

Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor

✍ Kyoko Inokura, Yasushi Onishi, Kenji Shimosegawa, Yoko Okitsu… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 68 KB

Coexistence of a JAK2 Mutated Clone May

Coexistence of a JAK2 Mutated Clone May Cause Hematologic Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

✍ Fava, Carmen; Cambrin, Giovanna Rege; Ferrero, Dario; Ulisciani, Stefano; Serra, 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 45 KB

Clonal chromosomal abnormalities in CD34

Clonal chromosomal abnormalities in CD34+/CD38− hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors

✍ Bumm, T; Deininger, J; Newell, A H; Lawce, H; Olson, S; Mauro, M; Druker, B; Dei 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 243 KB

Do chronic myeloid leukemia patients wit

Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?

✍ García-Gutiérrez, Valentin; Puerta, Jose Manuel; Maestro, Begoña; Casado Montero 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 548 KB